We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Canopus BioPharma Announces Positive Results in Human Study of Peptide Cancer Vaccine

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

Canopus BioPharma, Inc. announced that it has successfully completed the second phase of its cancer vaccine development.

The specialized laboratory study was analyzed at the Southern Research Institute in Birmingham, Alabama. The study used the blood of healthy human volunteers, vaccinated with Canopus Biopharma’s cancer vaccine peptides, which then demonstrated anti-cancer properties against a panel of 12 human cancer cell lines in tissue culture.

The successful human testing confirms that Canopus BioPharma’s proprietary, patented use of these cancer-targeted peptide antigens is effective as a vaccine against human cancer cells. When used as a vaccine in healthy volunteers, the peptide antigens generate antibodies that are non-toxic to normal cells, but significantly effective in destroying human cancer cells in-vitro.

In effect, the peptide antigens work by stimulating a person’s own immune system, to protect the individual from developing certain forms of cancer.